Labcorp Launches First FDA-Approved At-Home Screening Test for Colorectal Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 22 2026
0mins
Source: Newsfilter
- Innovative Home Screening: Labcorp has launched ColoSense®, the first FDA-approved RNA-based at-home colorectal cancer screening test, designed to reduce barriers to home screening through a simplified sample collection process, thereby improving screening rates in line with ACS and NCCN guidelines.
- Expanded Coverage: ColoSense is now available nationwide and is covered for eligible Medicare and Medicare Advantage beneficiaries, which is expected to enable more eligible adults to undergo colorectal cancer screening, particularly those facing barriers to screening.
- Strong Clinical Performance: The test demonstrates a 93% sensitivity for colorectal cancer in average-risk individuals and achieves 100% sensitivity for stage I colorectal cancer, allowing for early detection at the most treatable stage, significantly enhancing patient survival rates.
- Patient Support Services: Geneoscopy provides patient navigation support for ColoSense, assisting individuals in understanding their results and following recommended next steps, including colonoscopy after a positive result, further enhancing the screening experience and effectiveness of subsequent treatments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 284.390
Low
270.00
Averages
304.45
High
325.00
Current: 284.390
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Labcorp to Release Q2 2026 Financial Results on July 30
- Earnings Release Schedule: Labcorp is set to announce its Q2 2026 financial results before the market opens on July 30, 2026, highlighting its leadership in global laboratory services.
- Webcast Discussion: The company will host a webcast at 9:00 a.m. ET on the same day to discuss the financial results, enhancing transparency for investors regarding the company's performance.
- Information Access: The earnings press release and accompanying financial information will be available on the Labcorp Investor Relations website under the 'News & Events' section, facilitating easy access for investors.
- Replay Availability: A replay of the webcast will be accessible on the Investor Relations website for one year after the live event, ensuring investors can review the earnings content at their convenience.
See More
Labcorp Launches First RNA-Based At-Home Colorectal Cancer Screening Test
- Innovative Screening Solution: Labcorp's ColoSense® is the first RNA-based at-home colorectal cancer screening test approved by the FDA, designed to reduce barriers to home screening by simplifying the sample collection process, thereby improving early detection rates for colorectal cancer.
- Expanded Coverage: ColoSense is now available nationwide, with eligible Medicare and Medicare Advantage beneficiaries covered for the test, a policy update that is expected to significantly increase screening participation among the elderly population.
- Strong Clinical Performance: The test demonstrates 93% sensitivity for colorectal cancer in average-risk individuals and achieves 100% sensitivity for stage I colorectal cancer, ensuring timely detection of the disease at its most treatable stage, which is crucial for clinical outcomes.
- Patient Support Services: Geneoscopy offers navigation support to help users understand their test results and follow recommended next steps, including colonoscopy after a positive result, further enhancing the screening experience and health management capabilities for patients.
See More
Labcorp Launches First FDA-Approved At-Home Screening Test for Colorectal Cancer
- Innovative Home Screening: Labcorp has launched ColoSense®, the first FDA-approved RNA-based at-home colorectal cancer screening test, designed to reduce barriers to home screening through a simplified sample collection process, thereby improving screening rates in line with ACS and NCCN guidelines.
- Expanded Coverage: ColoSense is now available nationwide and is covered for eligible Medicare and Medicare Advantage beneficiaries, which is expected to enable more eligible adults to undergo colorectal cancer screening, particularly those facing barriers to screening.
- Strong Clinical Performance: The test demonstrates a 93% sensitivity for colorectal cancer in average-risk individuals and achieves 100% sensitivity for stage I colorectal cancer, allowing for early detection at the most treatable stage, significantly enhancing patient survival rates.
- Patient Support Services: Geneoscopy provides patient navigation support for ColoSense, assisting individuals in understanding their results and following recommended next steps, including colonoscopy after a positive result, further enhancing the screening experience and effectiveness of subsequent treatments.
See More
Labcorp Partners with Alliance for Clinical Trials on Colorectal Cancer Study
- Collaboration Launch: Labcorp Holdings Inc. has partnered with the Alliance for Clinical Trials to initiate a national multicenter clinical trial for newly diagnosed colorectal cancer patients, aiming to enhance participation in genetic testing, particularly for the approximately 10% of cases caused by inherited variants.
- Testing Method Evaluation: The trial will assess whether proactive outreach by healthcare providers can improve first-degree relatives' participation in cascade genetic testing, thereby enhancing communication of genetic risk among families and increasing early diagnosis potential.
- Impact of Multigene Testing: The study will also evaluate the impact of multigene panel testing on patients newly diagnosed with colorectal cancer, aiming to support more effective treatment options through scientific data, ultimately improving patient survival rates and quality of life.
- National Cancer Institute Support: Sponsored by the National Cancer Institute, the trial will leverage Labcorp's national scale and scientific expertise to ensure high-quality genetic testing services at participating sites, further advancing cancer research.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Trial Launch: Labcorp collaborates with the Alliance for Clinical Trials to initiate a national multicenter clinical trial aimed at increasing genetic testing participation among family members of colorectal cancer patients, which is expected to significantly enhance hereditary risk identification.
- Importance of Testing: Approximately 10% of colorectal cancer cases are linked to inherited variants, yet less than one-third of at-risk relatives undergo recommended genetic testing; this trial will assess the impact of proactive outreach by healthcare providers on testing participation.
- Multigene Testing Evaluation: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to drive the application of genetic testing in cancer management through scientific evidence.
- Support from NCI: Sponsored by the National Cancer Institute, the trial encompasses patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Genetic Testing Collaboration: Labcorp has partnered with the Alliance for Clinical Trials to conduct a national multicenter clinical trial aimed at increasing participation in genetic testing among family members of colorectal cancer patients, which is expected to enhance hereditary risk identification and improve preventive measures for patients and their families.
- Low Testing Rates: Research indicates that less than one-third of at-risk relatives receive recommended genetic testing, and this trial will assess whether proactive outreach by healthcare providers can improve this rate, thereby enhancing health management for family members.
- Impact of Multigene Testing: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to support more effective treatment plans through scientific evidence and improve overall patient outcomes.
- Support from National Cancer Institute: Sponsored by the National Cancer Institute, the trial will enroll patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care and improving patient outcomes through high-impact clinical research.
See More
Labcorp to Release Q2 2026 Financial Results on July 30
- Earnings Release Schedule: Labcorp is set to announce its Q2 2026 financial results before the market opens on July 30, 2026, highlighting its leadership in global laboratory services.
- Webcast Discussion: The company will host a webcast at 9:00 a.m. ET on the same day to discuss the financial results, enhancing transparency for investors regarding the company's performance.
- Information Access: The earnings press release and accompanying financial information will be available on the Labcorp Investor Relations website under the 'News & Events' section, facilitating easy access for investors.
- Replay Availability: A replay of the webcast will be accessible on the Investor Relations website for one year after the live event, ensuring investors can review the earnings content at their convenience.
See More
Labcorp Launches First RNA-Based At-Home Colorectal Cancer Screening Test
- Innovative Screening Solution: Labcorp's ColoSense® is the first RNA-based at-home colorectal cancer screening test approved by the FDA, designed to reduce barriers to home screening by simplifying the sample collection process, thereby improving early detection rates for colorectal cancer.
- Expanded Coverage: ColoSense is now available nationwide, with eligible Medicare and Medicare Advantage beneficiaries covered for the test, a policy update that is expected to significantly increase screening participation among the elderly population.
- Strong Clinical Performance: The test demonstrates 93% sensitivity for colorectal cancer in average-risk individuals and achieves 100% sensitivity for stage I colorectal cancer, ensuring timely detection of the disease at its most treatable stage, which is crucial for clinical outcomes.
- Patient Support Services: Geneoscopy offers navigation support to help users understand their test results and follow recommended next steps, including colonoscopy after a positive result, further enhancing the screening experience and health management capabilities for patients.
See More
Labcorp Launches First FDA-Approved At-Home Screening Test for Colorectal Cancer
- Innovative Home Screening: Labcorp has launched ColoSense®, the first FDA-approved RNA-based at-home colorectal cancer screening test, designed to reduce barriers to home screening through a simplified sample collection process, thereby improving screening rates in line with ACS and NCCN guidelines.
- Expanded Coverage: ColoSense is now available nationwide and is covered for eligible Medicare and Medicare Advantage beneficiaries, which is expected to enable more eligible adults to undergo colorectal cancer screening, particularly those facing barriers to screening.
- Strong Clinical Performance: The test demonstrates a 93% sensitivity for colorectal cancer in average-risk individuals and achieves 100% sensitivity for stage I colorectal cancer, allowing for early detection at the most treatable stage, significantly enhancing patient survival rates.
- Patient Support Services: Geneoscopy provides patient navigation support for ColoSense, assisting individuals in understanding their results and following recommended next steps, including colonoscopy after a positive result, further enhancing the screening experience and effectiveness of subsequent treatments.
See More
Labcorp Partners with Alliance for Clinical Trials on Colorectal Cancer Study
- Collaboration Launch: Labcorp Holdings Inc. has partnered with the Alliance for Clinical Trials to initiate a national multicenter clinical trial for newly diagnosed colorectal cancer patients, aiming to enhance participation in genetic testing, particularly for the approximately 10% of cases caused by inherited variants.
- Testing Method Evaluation: The trial will assess whether proactive outreach by healthcare providers can improve first-degree relatives' participation in cascade genetic testing, thereby enhancing communication of genetic risk among families and increasing early diagnosis potential.
- Impact of Multigene Testing: The study will also evaluate the impact of multigene panel testing on patients newly diagnosed with colorectal cancer, aiming to support more effective treatment options through scientific data, ultimately improving patient survival rates and quality of life.
- National Cancer Institute Support: Sponsored by the National Cancer Institute, the trial will leverage Labcorp's national scale and scientific expertise to ensure high-quality genetic testing services at participating sites, further advancing cancer research.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Trial Launch: Labcorp collaborates with the Alliance for Clinical Trials to initiate a national multicenter clinical trial aimed at increasing genetic testing participation among family members of colorectal cancer patients, which is expected to significantly enhance hereditary risk identification.
- Importance of Testing: Approximately 10% of colorectal cancer cases are linked to inherited variants, yet less than one-third of at-risk relatives undergo recommended genetic testing; this trial will assess the impact of proactive outreach by healthcare providers on testing participation.
- Multigene Testing Evaluation: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to drive the application of genetic testing in cancer management through scientific evidence.
- Support from NCI: Sponsored by the National Cancer Institute, the trial encompasses patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care.
See More
Labcorp Partners with Alliance for Clinical Trials to Enhance Genetic Testing in Colorectal Cancer
- Genetic Testing Collaboration: Labcorp has partnered with the Alliance for Clinical Trials to conduct a national multicenter clinical trial aimed at increasing participation in genetic testing among family members of colorectal cancer patients, which is expected to enhance hereditary risk identification and improve preventive measures for patients and their families.
- Low Testing Rates: Research indicates that less than one-third of at-risk relatives receive recommended genetic testing, and this trial will assess whether proactive outreach by healthcare providers can improve this rate, thereby enhancing health management for family members.
- Impact of Multigene Testing: The trial will also evaluate the impact of multigene panel testing on the care of newly diagnosed colorectal cancer patients, aiming to support more effective treatment plans through scientific evidence and improve overall patient outcomes.
- Support from National Cancer Institute: Sponsored by the National Cancer Institute, the trial will enroll patients and their relatives nationwide, reflecting Labcorp's ongoing commitment to advancing genetics-based approaches in cancer care and improving patient outcomes through high-impact clinical research.
See More
